Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

NCT02449343 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

NCT03792542 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

NCT03591666 ·Status: UNKNOWN ·Phase: PHASE2

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

NCT06838910 ·Status: RECRUITING ·Phase: PHASE2

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

NCT03527888 ·Status: UNKNOWN ·Phase: PHASE2

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

NCT02622932 ·Status: COMPLETED ·Phase: PHASE1

A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

NCT04787328 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

NCT03618238 ·Status: COMPLETED ·Phase: PHASE2

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

NCT06195228 ·Status: RECRUITING ·Phase: PHASE4

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

NCT05981157 ·Status: RECRUITING ·Phase: PHASE2

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05807880 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NCT05021328 ·Status: COMPLETED ·Phase: PHASE1

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

NCT03946943 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

NCT06062563 ·Status: UNKNOWN ·Phase: NA

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

NCT03672136 ·Status: UNKNOWN ·Phase: PHASE2

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

NCT04996758 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

NCT05490667 ·Status: UNKNOWN ·Phase: NA

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

NCT06611137 ·Status: RECRUITING ·Phase: PHASE2

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

NCT03623581 ·Status: UNKNOWN ·Phase: PHASE2

A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.

NCT07156643 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

NCT04958993 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

NCT07307443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy

NCT04507035 ·Status: UNKNOWN ·Phase: PHASE4

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

NCT05198531 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Metastatic Nasopharyngeal Carcinoma

NCT06886347 ·Status: RECRUITING ·Phase: PHASE1